Publication: 4737

Publication: 4737

Randomized Phase 2/3 Study of Conventional Chemotherapy +/- Uproleselan in Older Adults with Acute Myeloid Leukemia (AML) Receiving Intensive Induction Chemotherapy (Alliance A041701)

DOI

Google Scholar

Citation:

Meeting Instance:: ASH 2025
Year:: 2025
Type:: Abstract
Sub type:
Funding:: NCTN
Endpoint:: Primary
Analysis:: Primary
Data Sharing:: No-Data-Sharing
Status:: Presented/Published
Citation Status:: epub-ppub

Note:

Methodological:: No
Biospecimen:: No
SDC:: No

Parents:: None
Children:: None

Program:: OGC
Primary Committee:: Leukemia
Sec. Committees:

Pharmas:
Grants:: U10CA180821, U10CA180882, U10CA180820 (ECOG-ACRIN), U10CA180888 (SWOG);

Corr. Author:
Authors:: Geoffrey L. Uy Jun Yin Shira Dinner Daniel DeAngelo Jane L. Liesveld Jonathan Kolitz Adam Asch Olatoyosi Odenike Oudom Kour Rebecca E. Teske Korrie Skogen Kenneth Byrd Richard Little Andrew Carroll Krzysztof Mrozek AK Eisfeld John C. Byrd Anthony J. Jaslowski Harry Erba Mark Litzow Wendy Stock Richard M. Stone

Networks:: CROWN, KANSAS, LAPS-AL002, LAPS-IL036, LAPS-IL057, LAPS-MA036, LAPS-MN026, LAPS-MO011, LAPS-NC010, LAPS-OH007, LAPS-OK003, LAPS-PA015, NORTHWELL

Study: Alliance-A041701
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:: 2/3

Keywords: